Sirolimus: a potential chemopreventive agent.
Fernandez
Anthony
A
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Hu
Shasa
S
Kirsner
Robert S
RS
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D051379:Mice; D016377:Organ Transplantation / Q000009:adverse effects*; D020123:Sirolimus / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control*; D014467:Ultraviolet Therapy
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D020123:Sirolimus